ERBB2 and ovarian carcinoma: In the present study, we have utilized the intracellular drug delivery technology PCI to potentiate the cytotoxicity of the HER2-targeted recombinant immunotoxin, MH3-B1/rGel in HER2 overexpressing ovarian cancer cell lines.